Literature DB >> 31462501

Inhibition of NR4A1 Promotes ROS Accumulation and IL24-Dependent Growth Arrest in Rhabdomyosarcoma.

Erik Hedrick1, Kumaravel Mohankumar1, Alexandra Lacey1, Stephen Safe2.   

Abstract

Nuclear receptor 4A1 (NR4A1, Nur77) is overexpressed in rhabdomyosarcoma (RMS), and inactivation of NR4A1 (siNR4A1) or treatment with the NR4A1 antagonist 1,1-bis(3'-indoly)-1-(p-hydroxy-phenyl)methane (DIM-C-pPhOH) has antiproliferative and proapoptotic effects on RMS cells. However, the mechanism by which NR4A1 inhibition exerts these effects is poorly defined. Here, we report that NR4A1 silencing or inhibition resulted in accumulation of reactive oxygen species (ROS) and ROS-dependent induction of the tumor suppressor-like cytokine IL24 in RMS cells. Mechanistically, NR4A1 was found to regulate the expression of the proreductant genes thioredoxin domain-containing 5 (TXNDC5) and isocitrate dehydrogenase 1 (IDH1), which are downregulated in RMS cells following NR4A1 knockdown or inhibition. Silencing TXNDC5 and IDH1 also induced ROS accumulation and IL24 expression in RMS cells, suggesting that NR4A1 antagonists mediate their antiproliferative and apoptotic effects through modulation of proreductant gene expression. Finally, cotreatment with the antioxidant glutathione or IL24-blocking antibody reversed the effects of NR4A1 inhibition, demonstrating the importance of both ROS and IL24 in mediating the cellular responses. IMPLICATIONS: Overall, these data elucidate the mechanism by which NR4A1 inhibition functions to inhibit the proliferation, survival, and migration of RMS cells. ©2019 American Association for Cancer Research.

Entities:  

Year:  2019        PMID: 31462501      PMCID: PMC6825581          DOI: 10.1158/1541-7786.MCR-19-0408

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  50 in total

1.  Orphan nuclear receptor Nur77 promotes colorectal cancer invasion and metastasis by regulating MMP-9 and E-cadherin.

Authors:  Jing-Ru Wang; Wen-Juan Gan; Xiu-Ming Li; Yuan-Yuan Zhao; Ying Li; Xing-Xing Lu; Jian-Ming Li; Hua Wu
Journal:  Carcinogenesis       Date:  2014-07-26       Impact factor: 4.944

2.  Research resource: nuclear receptors as transcriptome: discriminant and prognostic value in breast cancer.

Authors:  George E O Muscat; Natalie A Eriksson; Karen Byth; Sherene Loi; Dinny Graham; Shalini Jindal; Melissa J Davis; Colin Clyne; John W Funder; Evan R Simpson; Mark A Ragan; Elizabeth Kuczek; Peter J Fuller; Wayne D Tilley; Peter J Leedman; Christine L Clarke
Journal:  Mol Endocrinol       Date:  2013-01-04

3.  PAX3-FOXO1A Expression in Rhabdomyosarcoma Is Driven by the Targetable Nuclear Receptor NR4A1.

Authors:  Alexandra Lacey; Aline Rodrigues-Hoffman; Stephen Safe
Journal:  Cancer Res       Date:  2016-11-18       Impact factor: 12.701

4.  The orphan nuclear receptor NR4A1 (Nur77) regulates oxidative and endoplasmic reticulum stress in pancreatic cancer cells.

Authors:  Syng-Ook Lee; Un-Ho Jin; Jeong Han Kang; Sang Bae Kim; Aaron S Guthrie; Sandeep Sreevalsan; Ju-Seog Lee; Stephen Safe
Journal:  Mol Cancer Res       Date:  2014-02-10       Impact factor: 5.852

5.  mda-7 (IL-24) Mediates selective apoptosis in human melanoma cells by inducing the coordinated overexpression of the GADD family of genes by means of p38 MAPK.

Authors:  Devanand Sarkar; Zao-Zhong Su; Irina V Lebedeva; Moira Sauane; Rahul V Gopalkrishnan; Kristoffer Valerie; Paul Dent; Paul B Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-11       Impact factor: 11.205

6.  Clinical ascertainment of health outcomes among adults treated for childhood cancer.

Authors:  Melissa M Hudson; Kirsten K Ness; James G Gurney; Daniel A Mulrooney; Wassim Chemaitilly; Kevin R Krull; Daniel M Green; Gregory T Armstrong; Kerri A Nottage; Kendra E Jones; Charles A Sklar; Deo Kumar Srivastava; Leslie L Robison
Journal:  JAMA       Date:  2013-06-12       Impact factor: 56.272

7.  Targeting oxidative stress in embryonal rhabdomyosarcoma.

Authors:  Xiang Chen; Elizabeth Stewart; Anang A Shelat; Chunxu Qu; Armita Bahrami; Mark Hatley; Gang Wu; Cori Bradley; Justina McEvoy; Alberto Pappo; Sheri Spunt; Marcus B Valentine; Virginia Valentine; Fred Krafcik; Walter H Lang; Monika Wierdl; Lyudmila Tsurkan; Viktor Tolleman; Sara M Federico; Chris Morton; Charles Lu; Li Ding; John Easton; Michael Rusch; Panduka Nagahawatte; Jianmin Wang; Matthew Parker; Lei Wei; Erin Hedlund; David Finkelstein; Michael Edmonson; Sheila Shurtleff; Kristy Boggs; Heather Mulder; Donald Yergeau; Steve Skapek; Douglas S Hawkins; Nilsa Ramirez; Philip M Potter; John A Sandoval; Andrew M Davidoff; Elaine R Mardis; Richard K Wilson; Jinghui Zhang; James R Downing; Michael A Dyer
Journal:  Cancer Cell       Date:  2013-12-09       Impact factor: 31.743

8.  Prognostic factors for postoperative survival among patients with rhabdomyosarcoma of the limbs.

Authors:  Shihong Ren; Zhan Wang; Xin Huang; Lingling Sun; Jinxiang Shao; Zhaoming Ye
Journal:  Cancer Manag Res       Date:  2018-10-03       Impact factor: 3.989

9.  Identification of target genes of PAX3-FOXO1 in alveolar rhabdomyosarcoma.

Authors:  Eun Hyun Ahn; Gabriela E Mercado; Marick Laé; Marc Ladanyi
Journal:  Oncol Rep       Date:  2013-06-03       Impact factor: 3.906

10.  Molecular targets and signaling pathways regulated by interleukin (IL)-24 in mediating its antitumor activities.

Authors:  Janani Panneerselvam; Anupama Munshi; Rajagopal Ramesh
Journal:  J Mol Signal       Date:  2013-12-30
View more
  5 in total

1.  Flavonoids kaempferol and quercetin are nuclear receptor 4A1 (NR4A1, Nur77) ligands and inhibit rhabdomyosarcoma cell and tumor growth.

Authors:  Rupesh Shrestha; Kumaravel Mohankumar; Greg Martin; Amanuel Hailemariam; Syng-Ook Lee; Un-Ho Jin; Robert Burghardt; Stephen Safe
Journal:  J Exp Clin Cancer Res       Date:  2021-12-14

Review 2.  The role and mechanism of TXNDC5 in diseases.

Authors:  Xueling Wang; Haoran Li; Xiaotian Chang
Journal:  Eur J Med Res       Date:  2022-08-08       Impact factor: 4.981

Review 3.  Therapeutic potential of NR4A1 in cancer: Focus on metabolism.

Authors:  Shan Deng; Bo Chen; Jiege Huo; Xin Liu
Journal:  Front Oncol       Date:  2022-08-16       Impact factor: 5.738

Review 4.  Targeting ferroptosis in osteosarcoma.

Authors:  Jiazheng Zhao; Yi Zhao; Xiaowei Ma; Benzheng Zhang; Helin Feng
Journal:  J Bone Oncol       Date:  2021-07-12       Impact factor: 4.072

5.  Thioredoxin Domain Containing 5 Suppression Elicits Serum Amyloid A-Containing High-Density Lipoproteins.

Authors:  Javier Sánchez-Marco; Roberto Martínez-Beamonte; Alicia De Diego; Tania Herrero-Continente; Cristina Barranquero; Carmen Arnal; Joaquín Surra; María A Navarro; Jesús Osada
Journal:  Biomedicines       Date:  2022-03-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.